LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q3 2025
Institutional positions in LAVA Therapeutics NV as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
LVTX is no longer listed, so this page shows Q3 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 21
- +2 vs. Q2 2025
- Shares held
- 10.3M
- +2.27M (+28.2%) vs. Q2 2025
- Total value
- $16.1M
- +$5.48M (+51.5%) vs. Q2 2025
- New holders
- 8
- 2 more added
- Sold out
- 6
- 1 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shay Capital LLC | 2,548,730 | $3.98M | 0.72% | +2,548,730 | New |
| Redmile Group, LLC | 2,074,372 | $3.24M | 0.31% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,970,610 | $3.07M | 2.83% | 00.0% | Unchanged |
| Sanofi | 1,919,455 | $2.99M | 1.15% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,149,345 | $1.79M | 0.79% | 00.0% | Unchanged |
| GTS Securities LLC | 200,000 | $312.0K | 0.01% | +200,000 | New |
| Rangeley Capital, LLC | 165,000 | $257.4K | 0.24% | +137,927+509.5% | Added |
| The PNC Financial Services Group, Inc. | 65,000 | $101.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 53,308 | $83.2K | 0.00% | +1,504+2.9% | Added |
| Royal Bank of Canada | 44,348 | $69.0K | 0.00% | +44,348 | New |
| Lepercq De Neuflize Asset Management LLC | 31,000 | $48.4K | 0.03% | 00.0% | Unchanged |
| JBF Capital, Inc. | 23,911 | $37.3K | 0.01% | +23,911 | New |
| XTX Topco Ltd | 21,727 | $33.9K | 0.00% | +21,727 | New |
| UBS Group AG | 15,871 | $24.8K | 0.00% | −509−3.1% | Reduced |
| Torno Capital, LLC | 15,000 | $23.4K | 0.00% | +15,000 | New |
| Geode Capital Management, LLC | 14,170 | $22.1K | 0.00% | 00.0% | Unchanged |
| Equitec Proprietary Markets, LLC | 12,500 | $19.5K | 0.12% | +12,500 | New |
| TSFG, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 400 | $636 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 300 | $468 | 0.00% | 00.0% | Unchanged |
| Smallwood Wealth Investment Management, LLC | 26 | $40 | 0.00% | +26 | New |
| Bruce & Co., Inc. | 0 | $0 | 0.00% | −521,874−100.0% | Sold out |
| Pathway Financial Advisors LLC | 0 | $0 | 0.00% | −102,500−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −46,900−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −34,412−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −14,236−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −11,600−100.0% | Sold out |